Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialVyome Holdings ( (HIND) ) has issued an announcement. On February 20, 2026, Vyome’s subsidiary Livechain, Inc. and its unit LICH AI Inc. entered into a Notes Purchase and Exchange Agreement with Remus Capital to acquire $5.77 million in senior secured convertible notes of Sociometric Solutions, Inc., d/b/a Humanyze, in an all-stock deal. As consideration, Livechain agreed to issue Remus roughly 211.2 million common shares, equal to 25% of Livechain’s fully diluted equity immediately before closing, and to reserve additional stock for employee compensation in connection with the transaction. Under the structure, Livechain has triggered a default and asset transfer so that LICH AI Inc. will assume substantially all of Humanyze’s assets, including intellectual property and trade secrets, and take direct control of its operations to build an AI-enabled HR analytics business. The related-party transaction, which was approved by Vyome’s audit committee and board with conflicted Remus-affiliated directors recusing themselves, is intended to reposition Livechain in the high-growth AI HR sector and create a potential path to a future uplisting, while limiting Vyome’s capital and operational exposure and offering upside for both Livechain and Vyome shareholders. On February 24, 2026, Vyome announced the agreement’s execution, highlighting Humanyze’s roots in the MIT Media Lab and its focus on science-based, AI-driven workforce analytics for large enterprises. The deal structure includes obligations for Remus to keep Humanyze active to manage select legacy liabilities and creates a framework for Livechain to raise its own capital independently as it integrates Humanyze and develops a scalable AI platform around human capital management. The most recent analyst rating on (HIND) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page. Spark’s Take on HIND Stock According to Spark, TipRanks’ AI Analyst, HIND is a Neutral. The score is held down primarily by deteriorating revenue, very large losses, and ongoing cash burn that increase financing/dilution risk. Technicals also indicate a sustained downtrend. Offsetting factors are modest: low current leverage and positive corporate updates around VT-1953’s perceived market potential, but these do not overcome the weak current financial profile. To see Spark’s full report on HIND stock, click here. More about Vyome Holdings Vyome Holdings, Inc., based in Cambridge, Mass., operates as a platform spanning the U.S.-India innovation corridor with an immediate focus on leveraging clinical-stage assets to treat immuno-inflammatory conditions while maintaining cost efficiency and high quality. Its subsidiary Livechain, Inc. is pursuing strategic alternatives in emerging technology sectors, intending to build an AI-driven platform focused on human capital, workforce intelligence and human relationship management. Livechain is currently traded on the OTC market under the ticker LICH and is evaluating AI-related acquisitions to expand its presence in the artificial intelligence space. Through these initiatives, Vyome seeks to capture value both as majority shareholder of Livechain and as a developer of differentiated healthcare innovations for patients and investors. Average Trading Volume: 888,238 Technical Sentiment Signal: Strong Sell Current Market Cap: $17.72M For an in-depth examination of HIND stock, go to TipRanks’ Overview page.